Table 1.

Baseline Characteristics and Therapy Distribution According to Age and Event Status

	Overall Group (n=1605)	≤45 years: No event (n=218)	≤45 years: Event (n=45)	46-65 years: No event (n=700)	46-65 years: Event (n=107)	≥65 years: No event (n=462)	≥65 years: Event (n=73)
Baseline Characteristics
Age, yearsa	59.2 ±13.7	36.4 ±6.5	35.7 ±8.3	57.1 ±5.4	57.5 ±5.8	73.5 ±5.6	74.0 ±5.8
Sex, % Maleb	78	65	69	80	81	80	100
Etiology, % Isch./Non-Isch.c	46/54	15/85	14/86	51/49	61/39	54/46	59/41
NYHA Classd	2.5 ±0.55	2.4 ±0.71	2.7 ±0.64	2.4 ±0.54	2.8 ±0.62	2.4 ±0.37	2.6 ±0.53
LVEF, %e	32.6=1 ±14.3	29.6 ±11.3	20.3 ±9.7	32.3 ±14.2	24.8 ±12.7	38.2 ±14.6	31.2 ±13.3
Event Type
death/transplant/LVADf	162/44/19	---	24/14/7	---	74/24/9	---	64/6/3
Therapy Distribution, %
ACE Inhibitor	73	81	68	64	62	79	63
Beta-Blocker	63	78	78	66	61	52	52

^aAll three age groups significantly different (p<0.001); No difference according to event status or interaction effects (p≥0.50)

^bSignificantly greater percent of females in the ≤45 years group compared to both others (p<0.001); Significantly greater percent of males in the ≥65 years group compared to both others (p<0.001)

^cPercentage of subjects in the ≤45 years group with non-ischemic etiology significantly greater than both others (p<0.001); Percentage of subjects with ischemic etiology suffering a cardiac event significantly greater compared to subjects not suffering a cardiac event in both the 45-65 and ≥65 years groups (p<0.05)

^dSignificant difference within each age group according to event status (p<0.001); No interaction effects (p>0.20)

^eAll three age groups significantly different (p<0.001); Significant difference within each group according to event status (p<0.001); No interaction effects (p>0.90)

^fSignificantly lower percentage of cardiac deaths in ≤45 years group compared to both others (p<0.05); Significantly higher percentage of cardiac deaths in ≥65 years group compared to both others (p<0.001)